Dyno Therapeutics

Company Type: Therapeutic development

Main focus: Developing innovative gene therapies with the aid of AI

Company stage: Pre-clinical

Diseases: Central nervous system diseases and genetic disorders of the eye

Genome-editing tool: N/A

Funding stage: Series A

Location: Watertown, Massachusetts, USA

Website: https://www.dynotx.com/

Pipeline:

Partners: Astellas, Roche, Spark, and Sarepta

Dyno Therapeutics is a biotech company using AI-driven methods to improve gene therapy delivery, specifically focusing on the design of synthetic AAV vectors. Its proprietary platform, CapsidMap™, generates optimised AAV capsids for targeting specific tissues more efficiently and overcoming limitations such as immune response and limited payload capacity in traditional viral vectors. Dyno’s approach has led to partnerships with major companies including Roche and Sarepta Therapeutics, focusing on gene therapies for central nervous system and eye disorders. The company’s platform leverages machine learning and high-throughput data to expand therapeutic developments.

Dyno Therapeutics